The U.S. Food and Drug Administration has approved Journavx™ (suzetrigine) 50mg oral tablets, the first drug approved in a new class of pain management medicine. Suzetrigine was the topic of the blog "A New Type of Pain Pill", see https://www.arthrofibrosis.info/post/a-new-type-of-pain-pill
Although suzetrigine has only been approved for treating acute pain, Vertex are investigating it for the treatment of peripheral neuropathic pain, painful diabetic peripheral neuropathy, and painful lumbrosacral radiculopathy. It may become the new standard for post-surgical pain.
Kayley